When you commit to Ride for Roswell, you’re making an impact on patients who are facing some of the most terrifying news of their life: a cancer diagnosis.
Glioblastoma is an aggressive form of brain cancer with a usually pretty scary prognosis. It doesn’t typically respond well to standard treatments like chemotherapy and radiation in the long run. Scientists at Roswell Park wanted to do something about that, so about 15 years ago, they set to work developing a new treatment option.
A brain tumor vaccine called SurVaxM now in a phase 2b clinical trial was developed at Roswell Park by Robert Fenstermaker, MD, Chair of Neurosurgery, and Michael Ciesielski, PhD, Director of the Neuro-Oncology Lab. This unique immunotherapy treatment vaccine, now being developed by MimiVax, targets survivin, a protein that helps cancer cells stay alive. Drs. Fenstermaker and Ciesielski have been moving the clinical trial forward every step of the way.
This endeavor has been funded by donor support since 2014 through the Roswell Park Alliance Foundation.”
Through clinical trials, this vaccine has given hope to many patients, including a 26-year-old man named Avery Richmond. Avery has been a farmer all his life. He has his wife Kelsey welcomed newborn son Teddy in 2022. Two months later, Avery collapsed, leading to the discovery of a lemon-sized tumor on his brain. Glioblastoma took this young family by surprise, but their resilience and the hope brought by the SurVaxM clinical trial have them giving thanks for every precious moment together.
Thanks to Ride for Roswell donors and participants, patients like Avery get more time with their loved ones and permission to hope for a brighter tomorrow.
SurVaxM was recently featured nationally on NBC News.